Drugs / uCD7 CART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07109518 | Jun 2025 → Jun 2028 expected | T lymphoblastic leukemia/lymphoma, acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | uCD7 CART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07109518 ↗ |
| Known as | Universal CD7 CART | “universal CD7 CART (uCD7 CART) cells” NCT07109518 ↗ |
| Modality | Cell therapy | “universal CD7 CAR-T cells” NCT07109518 ↗ |
| Route | Intravenous | “uCD7 CART cells will be administered intravenously” NCT07109518 ↗ |
| Target | CD7 | “universal CD7 CAR-T cells” NCT07109518 ↗ |